Please login to the form below

Not currently logged in
Email:
Password:

Forest diabetes drug study fails

Forest's neuropathic pain drug, radiprodil, has missed its primary endpoint in a phase II study

Radiprodil (RGH-896), in development by Forest Laboratories for the treatment of neuropathic pain associated with diabetic peripheral neuropathy missed its primary endpoint in a phase II study compared to placebo.

Forest and its partner on the drug, Gedeon Richter, said that they have not yet made a determination about whether to continue development of the product, but will do so in the coming weeks after reviewing the complete study database.

The drug is part of a wider development partnership signed between Forest and Budapest, Hungary-based Richter in 2005. The agreement gave Forest exclusive rights to the product in the US and Canada in return for undisclosed upfront and milestone payments, research funding and royalties.

Radiprodil targets a specific portion of the NMDA receptor that may be involved in the transmission of pain, an approach that the companies hoped would yield improvements in efficacy and the side effect profile compared to currently available treatments.

However, top-line results from the phase II dose-response trial failed to show statistically significant or clinically meaningful reductions in mean daily pain scores compared to placebo, which was the study's primary endpoint. The 14-week study enrolled about 450 patients.

Forest and Richter are also developing radiprodil for other chronic neuropathic pain conditions.

29th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics